Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment Journal of Medicinal Chemistry Forget GLP 1: Amylin Wants to Be the Next Big Thing ConscienHealth Does receptor balance matter? Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP 336 on metabolic parameters in preclinical models ScienceDirect Pharmacy Phase III REDEFINE trials at #ADA2025 reveal that once weekly CagriSema (semaglutide + cagrilintide) delivers impressive weight loss in adults without diabetes and in those with type 2 #diabetes, alongside favorable